Euthymics Completes Enrollment in TRIADE, its Advanced Trial of Amitifadine for Major Depressive Disorder

Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB- 1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD).

 

Press Release-TRIADE enrollment completion